Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. / Kissow, Hannelouise; Hartmann, Bolette; Holst, Jens Juul; Poulsen, Steen Seier.

I: Gut, 20.10.2012.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Kissow, H, Hartmann, B, Holst, JJ & Poulsen, SS 2012, 'Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis', Gut. https://doi.org/10.1136/gutjnl-2012-303280

APA

Kissow, H., Hartmann, B., Holst, J. J., & Poulsen, S. S. (2012). Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut. https://doi.org/10.1136/gutjnl-2012-303280

Vancouver

Kissow H, Hartmann B, Holst JJ, Poulsen SS. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut. 2012 okt 20. https://doi.org/10.1136/gutjnl-2012-303280

Author

Kissow, Hannelouise ; Hartmann, Bolette ; Holst, Jens Juul ; Poulsen, Steen Seier. / Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. I: Gut. 2012.

Bibtex

@article{82575ba5100e4ba89768722ac44f55e2,
title = "Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis",
abstract = "BACKGROUND: Glucagon-like peptide-2 (GLP-2) has been suggested for the treatment of mucositis, but the peptide has also been shown to accentuate colonic dysplasia in carcinogen-treated mice. Recently, an effect on intestinal growth was discovered for glucagon-like peptide-1 (GLP-1), OBJECTIVE: To determine whether endogenous GLP-1 contributes to the healing processes and if exogenous GLP-1 has a potential role in treating mucositis. METHODS: Mice were injected with 5-fluorouracil (5-FU) or saline to induce mucositis and were then treated with GLP-1, GLP-2, GLP-2 (3-33), exendin (9-39) or vehicle. The mice were sacrificed 48 or 96 h after the 5-FU injections. The end points were intestinal weight, villus height, proliferation and histological scoring of mucositis severity. Rats were injected with 5-FU or saline, and after 48 h, blood was drawn and analysed for GLP-1 and GLP-2 concentration. RESULTS: GLP-1 and GLP-2 significantly prevented the loss of mucosal mass and villus height and significantly decreased the mucositis severity score in the duodenum and jejunum 48 h after chemotherapy. The effect was equivalent. Exendin (9-39) reduced the intestinal weight 96 h after chemotherapy. The GLP-1 levels in blood were increased more than 10-fold, and GLP-2 levels were increased sevenfold. CONCLUSIONS: GLP-1 and GLP-2 were secreted after intestinal injury, and recovery was delayed after treatment with exendin (9-39), indicating an important role for the peptides in the protection of the intestine from injury. GLP-1 treatment ameliorated mucositis, which suggests that mucositis and other acute intestinal disorders might benefit from treatment with GLP-1 analogues.",
author = "Hannelouise Kissow and Bolette Hartmann and Holst, {Jens Juul} and Poulsen, {Steen Seier}",
year = "2012",
month = "10",
day = "20",
doi = "10.1136/gutjnl-2012-303280",
language = "English",
journal = "Gut",
issn = "0017-5749",
publisher = "B M J Group",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis

AU - Kissow, Hannelouise

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Poulsen, Steen Seier

PY - 2012/10/20

Y1 - 2012/10/20

N2 - BACKGROUND: Glucagon-like peptide-2 (GLP-2) has been suggested for the treatment of mucositis, but the peptide has also been shown to accentuate colonic dysplasia in carcinogen-treated mice. Recently, an effect on intestinal growth was discovered for glucagon-like peptide-1 (GLP-1), OBJECTIVE: To determine whether endogenous GLP-1 contributes to the healing processes and if exogenous GLP-1 has a potential role in treating mucositis. METHODS: Mice were injected with 5-fluorouracil (5-FU) or saline to induce mucositis and were then treated with GLP-1, GLP-2, GLP-2 (3-33), exendin (9-39) or vehicle. The mice were sacrificed 48 or 96 h after the 5-FU injections. The end points were intestinal weight, villus height, proliferation and histological scoring of mucositis severity. Rats were injected with 5-FU or saline, and after 48 h, blood was drawn and analysed for GLP-1 and GLP-2 concentration. RESULTS: GLP-1 and GLP-2 significantly prevented the loss of mucosal mass and villus height and significantly decreased the mucositis severity score in the duodenum and jejunum 48 h after chemotherapy. The effect was equivalent. Exendin (9-39) reduced the intestinal weight 96 h after chemotherapy. The GLP-1 levels in blood were increased more than 10-fold, and GLP-2 levels were increased sevenfold. CONCLUSIONS: GLP-1 and GLP-2 were secreted after intestinal injury, and recovery was delayed after treatment with exendin (9-39), indicating an important role for the peptides in the protection of the intestine from injury. GLP-1 treatment ameliorated mucositis, which suggests that mucositis and other acute intestinal disorders might benefit from treatment with GLP-1 analogues.

AB - BACKGROUND: Glucagon-like peptide-2 (GLP-2) has been suggested for the treatment of mucositis, but the peptide has also been shown to accentuate colonic dysplasia in carcinogen-treated mice. Recently, an effect on intestinal growth was discovered for glucagon-like peptide-1 (GLP-1), OBJECTIVE: To determine whether endogenous GLP-1 contributes to the healing processes and if exogenous GLP-1 has a potential role in treating mucositis. METHODS: Mice were injected with 5-fluorouracil (5-FU) or saline to induce mucositis and were then treated with GLP-1, GLP-2, GLP-2 (3-33), exendin (9-39) or vehicle. The mice were sacrificed 48 or 96 h after the 5-FU injections. The end points were intestinal weight, villus height, proliferation and histological scoring of mucositis severity. Rats were injected with 5-FU or saline, and after 48 h, blood was drawn and analysed for GLP-1 and GLP-2 concentration. RESULTS: GLP-1 and GLP-2 significantly prevented the loss of mucosal mass and villus height and significantly decreased the mucositis severity score in the duodenum and jejunum 48 h after chemotherapy. The effect was equivalent. Exendin (9-39) reduced the intestinal weight 96 h after chemotherapy. The GLP-1 levels in blood were increased more than 10-fold, and GLP-2 levels were increased sevenfold. CONCLUSIONS: GLP-1 and GLP-2 were secreted after intestinal injury, and recovery was delayed after treatment with exendin (9-39), indicating an important role for the peptides in the protection of the intestine from injury. GLP-1 treatment ameliorated mucositis, which suggests that mucositis and other acute intestinal disorders might benefit from treatment with GLP-1 analogues.

U2 - 10.1136/gutjnl-2012-303280

DO - 10.1136/gutjnl-2012-303280

M3 - Journal article

C2 - 23086829

JO - Gut

JF - Gut

SN - 0017-5749

ER -

ID: 45041286